Your Health, We Care
Exkivity is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test , whose disease has progressed on or after platinum-based chemotherapy.
This indication is approved under accelerated approval based on overall response rate and duration of response . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
from FDA，2023.09
Exkivity is suitable for specific non-small cell lung cancer(NSCLC).【more】
Release date：2026-01-06Recommended：6
Exkivity offers a new treatment option for NSCLC patients with EGFR exon 20 inse···【more】
Release date：2024-08-07Recommended：217
Exkivity provides a new treatment option for NSCLC patients with EGFR exon 20 in···【more】
Release date：2024-08-07Recommended：192
Exkivity is an innovative, oral, small molecule tyrosine kinase inhibitor (TKI) ···【more】
Release date：2024-08-07Recommended：180
